Pharmacy

Your Article Summary

See Latest Articles

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Forest Laboratories, 06/01/09

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced results from additional analyses of their Phase 2b study assessing the safety and efficacy of the novel, first-in-class agent linaclotide in 419 patients with irritable bowel syndrome with constipation. Previous analyses of these data indicated that once-daily oral dosing with linaclotide, across a range of doses, significantly improved abdominal symptoms, bowel habits, and global assessments over the 12-week treatment period.

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09

Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09

Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09

 See all of Major Studies

Today in Stomach/GI...keeping you current

Receive free subspecialty "5-minute updates" via email

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Journal of Viral Hepatitis, 12/17/09

Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy
Langenbeck's Archives of Surgery, 12/17/09

The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09

 See all of Stomach/GI